Skip to main content

Table 1 General characteristics of the whole group and the two subgroups according to the presence of an ultrasound goiter

From: Systematic thyroid screening in myotonic dystrophy: link between thyroid volume and insulin resistance

Patient characteristics

Whole group

UsGoiter

UsNonGoiter

p-value

Number of patients (N; %)

N = 115

N = 44 (38.3)

N = 71 (61.7)

 

Age (mean ± SD, years)

45.1 ± 12.2

46.6 ± 9.7

44.1 ± 13.5

.26

Sex

 Female ♀ (n/N; %)

71/115 (61.7)

28/44 (63.6)

43/71 (60.6)

.86

 Minimum of one child (n/N; %)

45/71 (63.4)

18/28 (66.7)

27/43 (62.8)

.74

Smoking habits (n/N; %)

45/105 (42.9)

17/44 (38.6)

28/60 (46.7)

.36

Clinical forms (n/N; %)

 Congenital form

5/115 (4.3)

2/44 (4.5)

3/71 (4.2)

.88

 Infantile form

14/115 (12.2)

5/44 (11.4)

9/71 (12.7)

.76

 Juvenile form

21/115 (18.3)

13/44 (29.5)

8/71 (11.3)

.08

 Adult form

57/115 (49.6)

31/44 (70.5)

26/71 (36.6)

.09

 Late onset form

18/115 (15.6)

6/44 (13.6)

12/71 (16.9)

.10

Weight (mean ± SD, kg)

72.5 ± 18.0

78.2 ± 18.6

69.6 ± 16.8

.011

BMI (mean ± SD, kg/m2)

26.4 ± 6.5

28.1 ± 7.1

25.0 ± 5.9

.013

Number of CTG repeats (median (IQR))

500 (260–850)

500 (300–850)

515 (254–785)

.90

CPK (median (IQR); IU/L)

204 (108–293)

217 (106–312)

186 (112–278)

.56

Obstructive sleep apnea syndrome (n/N; %)

65/115 (56.5)

27/44 (61.4)

38/71 (53.5)

.55

 CPAP (n/N; %)

40/65 (61.5)

16/27 (35.6)

24/38 (33.8)

.89

Pacemaker or defibrillator (CIED) (n/N; %)

28/115 (24.3)

13/44 (29.5)

15/71 (21.1)

.34

  1. Abbreviations: Us Ultrasound, SD standard deviation, IQR Interquartile, BMI Body mass index, CPK Creatinine phosphokinase, CPAP Continuous positive airway pressure, CIED Cardiovascular implantable electric device, CTG cytosine-thymidine-Guanine
  2. Clinical forms: (1) congenital form: neonatal (mild to severe) hypotonia, respiratory distress, sucking or swallowing difficulties, or skeletal deformities detected at birth or during the first month of life; (2) infantile form: clinical onset from one month to 10 years; (3) juvenile form: onset at 11–20 years; (4) adult form: onset at 21–40 years; (5) late-onset form: onset after 40 years